Ozempic / Wegovy (GLP-1) Mass Tort Case Leads
Reach patients who suffered severe gastrointestinal injuries and other serious side effects from semaglutide-based GLP-1 receptor agonist medications.
Ozempic / Wegovy GLP-1 Litigation
Ozempic and Wegovy, both semaglutide-based GLP-1 receptor agonists manufactured by Novo Nordisk, have been linked to severe gastrointestinal side effects that were not adequately disclosed on product labeling. Patients prescribed these medications for diabetes or weight loss have reported gastroparesis, bowel obstruction, and pancreatitis, among other serious conditions. Lawsuits allege the manufacturer failed to warn about the full scope and severity of these risks.
Associated Conditions
- Gastroparesis (stomach paralysis)
- Bowel obstruction
- Pancreatitis
- Gallbladder disease
- Intestinal blockage
- Severe nausea and vomiting requiring hospitalization
- Ileus (intestinal dysfunction)
Claimant Eligibility
- Prescribed Ozempic, Wegovy, or other semaglutide-based medication
- Experienced severe gastrointestinal side effects during or after use
- Required hospitalization or emergency treatment due to side effects
- Diagnosed with gastroparesis, bowel obstruction, or pancreatitis
- Side effects occurred while using or shortly after discontinuing the medication
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Ozempic legal marketing campaigns: how we acquire cases
Ozempic case acquisition runs as a multi-channel program, not a single ad buy. Product liability and class action claimants research their condition long before they contact a lawyer, so we meet potential clients at each stage — paid demand capture for people already searching, paid social and traditional media for people who have not yet connected their injury to the litigation, and organic search for the long research tail.
Digital marketing channels
- Google Ads and paid search demand capture
- Meta and paid social prospecting by exposure profile
- Mass tort search engine optimization for the research tail
- OTT and connected TV retargeting
Traditional media channels
- Broadcast and cable TV in qualifying DMAs
- Radio and streaming audio
- Direct response print in occupational verticals
- Earned media and litigation PR support
How the channel mix is built, budgeted, and measured is covered in our mass tort marketing guide. For intake handling once the lead lands, see mass tort intake.
Ozempic / Wegovy (GLP-1) Lawsuit Updates (August 2026)
Current status of the Ozempic / Wegovy (GLP-1) litigation, tracked monthly so your intake team and marketing spend stay aligned with where the docket actually is.
- MDL
- MDL 3094
- Court
- E.D. Pa.
- Pending cases
- 3,928
- Reported
- August 2026
Current posture: GLP-1 injury claims consolidated; general causation work ongoing.
The GLP-1 MDL recorded 3,928 pending cases. MDL 3094 covers personal injury actions arising from glucagon-like peptide-1 receptor agonists, including gastroparesis and vision-loss allegations.
Docket tracking reported growth past 4,700 filed actions across the GLP-1 litigation as awareness of the claims expanded.
Case counts and procedural posture are compiled from JPML MDL statistics reporting and public court dockets, and are provided for law firm campaign planning. This is not legal advice and is not a prediction of any case outcome.
Running a Ozempic mass tort marketing campaign
Common questions from law firms about Ozempic lawsuit lead generation and campaign management.
- What does a Ozempic mass tort marketing campaign include?
- A Ozempic mass tort marketing campaign from Mass Tort Marketing Agency covers multi-channel strategy across Meta, Google PPC, OTT and connected TV, traditional media, and mass tort search engine optimization; compliant ad creative; TCPA-verified intake; claimant qualification against your Ozempic case criteria; and signed-retainer reporting. Performance is measured on cost per signed retainer, not raw lead volume.
- How do you generate Ozempic mass tort case leads?
- Ozempic mass tort case leads are generated through paid social and search campaigns aimed at the specific exposure and injury profile of the litigation, supported by organic content that captures claimants already researching their condition. Every lead is a real, consented claimant — we do not buy aggregated lists or resell shared data.
- What do Ozempic legal marketing campaigns cost?
- Ozempic legal marketing campaigns are quoted and reported on cost per signed retainer (CPSR), so spend ties directly to signed cases rather than lead count. Cost per retainer varies by tort based on claimant prevalence, media competition, and how tight your case criteria are. We scope a per-tort figure before any spend commitment.
- Are Ozempic leads exclusive to my firm?
- Yes. Every Ozempic lead is delivered to one firm only — never resold, syndicated, or shared with competing firms. Your firm owns the contact data, consent records, and call recordings.
- How are Ozempic claimants qualified before delivery?
- Each Ozempic claimant is screened against tort-specific facts (exposure windows, injury markers, and state eligibility) and carries a certified TrustedForm or Jornaya consent record — preserving the exact disclosure language shown at submission — before the lead reaches your intake team.
- How fast can a Ozempic case acquisition program scale?
- A Ozempic mass tort case acquisition program typically moves from scoping to live media inside two weeks, with volume ramped against your docket capacity rather than pushed to a fixed budget. Volume can be scaled up or down by tort month to month as the litigation posture changes.
Get Ozempic campaign pricing on a 30-minute call
We will walk your Ozempic case criteria, current cost per signed retainer, and the volume your docket can absorb — and tell you plainly if this tort is not a fit right now.
See how every lead is qualified on our mass tort leads page, read the full mass tort marketing guide, or compare providers in our top mass tort marketing firms guide.